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Malaria is a global disease of importance, especially in the sub-Saharan African 
region, where malaria accounts for great losses economically and to life. Fight to 
eliminate this disease has resulted in reduced disease burden in many places where 
the diseases is endemic. Elimination strategies in most places is focus on the use of 
treated nets and drug application. Exposure of malaria parasites to anti-malaria 
drugs have led to the evolution of drug resistance in both parasites and host. 
Development of drug resistance vary but, studies on adaptive drug resistance has 
implications and consequences. Our knowledge of this consequences are limited 
but important for the pursuit of an uninterrupted malaria elimination agenda. This 
chapter draws our attention to this risks and recommends interventions.
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1. Introduction
1.1 Malaria - a global infectious disease
Malaria is a global deadly communicable disease [1], caused by plasmodium 
species, an apicomplexan microbe transmitted by the mosquito vector. Five major 
plasmodia parasites (P falciparum, P vivax, P ovale, P malariae and P knowlesi)  
have been implicated in malaria infections [2]. Of these, Plasmodium falciparum 
(P. falciparum) and Plasmodium vivax (P. vivax) are more widely distributed [3]. In 
sub-Saharan Africa, P. falciparum is the cause of most malaria cases while P. vivax 
is reported to cause most of the malaria cases in Asia; P. falciparum cause more fatal 
disease [4].
In 2019 alone, about 229 million positive malaria infections were reported 
globally, mortality from was estimated at about 409,000, with children under 
5 years accounting for about 67% of death [5]. The disease is common among 
in poor communities [6], especially rural communities of the underdeveloped/
developing countries of the world. Economic, social and health importance of 
this disease in terms of loss of life (particularly; young children), reduction in 
productivity of affected adult population, and negative social and health implica-
tion of the disease makes it one of the high ranking microbial, infectious disease 
in the world.
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1.2 Malaria elimination agenda
Among the diseases which have great public health impact, malaria is a signifi-
cant public health concern [7–9]. The fight to eliminate malaria is an aged long 
battle globally. Elimination programmes were launched after the Second World 
War [6], with chloroquine as the major frontline anti-malaria drug [10] and 
Dichlorodiphenyltrichloroethane DDT used for vector control [11]. Malaria elimina-
tions efforts in Africa began with the World Health Organisation (WHO) roll back 
malaria initiatives started in 1998 [1]; these efforts focused on entomology control 
(to reduce transmitting vectors) using indoor insecticides, and treated mosquito 
nets introduced for protection and prevention [6].
The success of these elimination programmes is why over one hundred countries 
have been awarded malaria free status [12] and thirty-four others accorded elimina-
tion status [13], and most malaria endemic countries working very hard towards the 
attainment of elimination status. Today the disease burden continues to decrease 
across the world [14] relative to the era, before the launch of the global elimination 
programmes.
Success stories leading to this elimination stage in malaria control had been 
heavily dependent on traditional entomology surveillance and drug use. However, 
the plasmodium is a ubiquitous parasites that has evolved, complex systems of 
survival [15]. Among these survival strategies is the development of drug resistance 
to nearly all know malaria drugs. Resistance to chloroquine (the major frontline 
medicine for the treatment of malaria) was reported and widespread [13] long 
before the roll-back-malaria initiatives. Better understanding of the biology of the 
parasites and the life cycle led to the development of a range of other anti-malaria 
drugs some of which are still actively being used, but resistance to almost all know 
malaria drugs have been reported [16–19].
Drug resistance vary, and is transferable from pathogen to host [20]. Of the 
different types of drug resistance, adaptive drug resistance is usually not perma-
nent, but is capable of producing strains of parasites not targeted by known drugs. 
This chapter aims at reviewing the different types of drug resistance with focus on 
adaptive drug resistance in plasmodium and the implication to malaria elimination 
programme.
2. Brief history of anti-malaria drug resistance
The fight against drug resistance in pathogenic microbes is global. The life of 
these microbes are so inter-twined with human wellness that if overlooked could be 
very costly in terms of treatment cost and loss of life. As efforts are being up-scaled 
towards malaria elimination, the issue of drug resistance continues to surface as 
a major challenge to cope with. This is because the malaria parasite continues to 
evolve and regularly develop mechanisms for surviving the toxic effect of drugs. 
These mechanisms result with fixed mutations in the genetic architecture that con-
fers fitness and resistance to withstand or evade targeting drugs, thereby hindering 
or completely preventing binding between drug compounds and their target.
The history of evolution of drug resistance in plasmodium dates back to the 
1930s when chloroquine (CQ ) resistance in P. falciparum arose independently in 
Columbia and Thailand [21], and rapidly spread throughout the world. Research 
efforts to truncate this spread led to the development of different variants of 
malaria drugs to replace CQ. However, the plasmodium in it’s unique way continue 
to adapt and evolve new mutations for survival and resistance to drugs which 
are harmful to it [22]. Advances in molecular technology has made it possible to 
3
Adaptive Drug Resistance in Malaria Parasite: A Threat to Malaria Elimination Agenda?
DOI: http://dx.doi.org/10.5772/intechopen.98323
uncover different mutations in the plasmodium parasites associated with drug 
resistance (Table 1). Evolution of these mutations are dynamic and difficult could 
be difficult to track and eliminate, especially when novel parasite results, against 
which known anti-malaria drugs is ineffective.
3. Drug resistance types: how much do we know in plasmodium?
Drug resistance types include Intrinsic, acquired and adaptive resistance. 
Intrinsic drug resistance is a natural phenomenon, and an innate ability in pathogen 
for resisting drug or harmful substance without prior record of susceptibility  
[30, 31], pathogens do not necessarily develop mutation for this to occur [32]. 
Acquired drug resistance builds up in human host, and makes them unresponsive 
to a drug that should normally eliminate known pathogenic parasite from the host 
system [33], these are both stable forms of drug resistance. Adaptive resistance  
[34, 35] develops in a pathogen in response to stimuli [36].
While “intrinsic and acquired resistance are stable and can be transmitted 
vertically to subsequent generations “[32] adaptive resistance is temporal, unstable, 
and is often lost ([17]; [37]). [38] observed that “unstable adaptation contains 
modulation of gene expression, which results in phenotypic changes due to changes 
in environmental markers that are sensed by the microorganisms” but it is not 
certain how long this resistance is, or could be sustained [39]. Adaptive resistance 
is acquired through mutation and binding genetic plasticity that enables transfer of 
genes [20] from parasites to host. These different mode of drug resistance have been 
extensively studied and reported for bacteria [36, 40–42], but not much is seen in 
literature regarding adaptive resistance in plasmodium.
4. Adaptive drug resistance has implications and consequences
Development of drug resistance interferes with disease control, increase the cost 
of treatment and management of control programs and if not quickly address could 
thwart control programmes. The evolution of drug resistance in malaria parasites 
have been a focus of many research but there is a dearth of information regarding 
adaptive resistance in malaria parasite and the consequence in their human hosts. It 
is quite understandable since adaptive resistance only confers a temporal resistance 
Mutation sites associated with drug resistance in plasmodium References
Mutation resulting in polymorphism at the position 76 (K76T) in the transmembrane 
protein, known as Plasmodium falciparum chloroquine resistance transporter 
(PfCRT).
[23, 24]
The N86Y and Y184F amino-terminal mutations falciparum multidrug resistance 
transporter 1 (PfMDR1) has been implicated commonly in CQ and other anti-malaria 
drug resistance in Asian and African parasites.
[17, 25, 26]
Mutation of dihydrofolate reductase (DHFR) associated with Plasmodium falciparum 
sulfadoxine-pyrimethamine resistance.
[27]
Mutation of dihydropteroate synthetase (DHPS) enzymes implicated in Plasmodium 
falciparum sulfadoxine-pyrimethamine resistance.
[27]
mutations in pvmdr1, pvcrt-o, pvdhfr, and pvdhps genes in temperate-zone of P. vivax 
associated with malaria drug resistance
[28, 29]
Table 1. 
Common mutations associated with P. falciparum malaria drug resistance.
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and is reversible. Although temporal and reversible, The possibility of mutation and 
evolution of a unique strain of parasite is possible, on which known drugs would be 
ineffective. However, the period between active activation of adaptive resistance in 
plasmodium, the product of activation (whether lethal or not, or novel and insensi-
tive to known drugs or not), the consequence in gene transfer to host and a host of 
other factors are unknown.
5.  Discovering and tackling adaptive drug resistance in plasmodium: 
recommendations
Evolution of resistance to drugs is a survival mechanism influenced by many 
factors that produce mutation in the parasites. Common among causes of resistance 
is exposure to non-lethal doses of anti-malaria drugs [15]. Malaria parasites have 
unique ability to evolving mechanisms for evading the immune response in humans 
[43] and they are actively evolving resistance to anti-plasmodia drugs [44]. But 
there is a dearth of information are to the effect of plasmodia resistance to drug, 
especially adaptive resistance, which though is temporal, could influence the devel-
opment of novel plasmodium stains not targeted by currently available anti-malaria 
drug. This development is a threat to malaria elimination agenda and should not be 
encouraged.
A host of resistance gene markers in plasmodium for drug resistance is an 
active field of malaria research [16, 18, 19, 45, 46], and still counting, but not 
much is written about the role or influence of adaptive resistance on these markers 
this is a conspicuous research gap in malaria biology and genetics requiring urgent 
attention. Selective sweep resulting in sudden change in an advantageous gene 
under strong positive selection [47] has been reported as product of evolution of 
resistance to drug. It is possible to scanning the genome for signature of selective 
sweeps, to identify genes undergoing adaptive evolution [48]. Similar studies 
revealed the mutations in presently known markers used in the study of malaria 
drug resistance [49–52], but none is focused on adaptive resistance. This kind of 
studies leverage of the NEXT GENERATION sequencing technology which is very 
limited and still very expensive in developing countries, especially in countries 
with no direct funding of research by government, where malaria is endemic.
6. Pertinent questions and suggestions for the way forward
Is adaptive resistance in malaria parasites a challenge? Does it have a significant 
influence on combating and elimination of malaria particularly in malaria endemic 
regions in Africa? Understanding the effects of adaptive malaria drug resistance, 
in plasmodium, the vector and the human host will greatly contribute to malaria 
elimination agenda and reposition the malaria elimination programmes across the 
world with focus on sub-Saharan Africa as the hub. In addition, different popula-
tions respond differently to the same drugs. These differential responses are influ-
enced by genetic variability in different ethnic groups within a population, which in 
turn can be associated with variation in resistance to given drugs. Identification of 
genes and gene pathways involved in adaptive resistance is also vital for developing 
markers for prediction and diagnosis and should be pursued.
Kim and Schneider [48] observed that, “by examining selective sweeps in 
many endemic areas with different demographic and epidemiologic characteris-
tics” it would be possible to identify factors associated with adaptive resistance 
to malaria drugs and track epidemiological variables [53–56] for transmission 
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and development of treatment regimes, accurate drug prescription and be able to 
determine costs of resistance. Understanding the implication and consequences of 
adaptive resistance alongside other forms of drug resistances will play significant 
role in policy formulation and implementation for disease control, give vivid 
picture of how to manage malaria control and modelling of disease transmission.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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